It’s unclear what impact a change in presidential administration will have on the proposal to widen access for those with obesity.

Share on Facebook Share on Twitter Under a new rule the Biden administration proposed on Tuesday, millions of Americans with ...

Mounjaro is a treatment for Type 2 diabetes that activates GIP and GLP-1 pathways to help regulate blood sugar. It’s part of ...

Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...

The microbial therapeutic products market is forecast to grow from USD 17.11 billion in 2022 to USD 30.55 billion by 2030, ...

The anti-obesity drug market has expanded significantly in recent years, with the Food and Drug Administration approving a ...

The Biden administration plans to require Medicare and Medicaid to offer coverage of weight loss medications for people seeking obesity treatment.The new rule, which was proposed by the administration ...

About 42% of U.S. adults are obese, the CDC says. GLP-1 medications have changed the picture for people hoping to reduce ...

The White House said it's moving to make the federal health insurance plans pay for anti-obesity drugs such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound for people who are obese, even if they don ...

The Biden administration proposed a rule to let Medicare and Medicaid cover obesity drugs like Ozempic. Millions would ...

Millions of obese Americans would get access to popular weekly injectables that would help them shed pounds quickly if a $35 ...

Should employers, patients or insurers cover the $411 billion annual cost for GLP-1 drugs? U.S. healthcare industry grapples with this question as demand grows.